Allogeneic stem cell transplantation for high-risk acute leukemia and maintenance therapy: no time to waste

Abstract

This article has a companion Counterpoint by Soiffer.

Conflict of interest statement

Conflict-of-interest disclosure: B.L.S. reports income for advisory roles from Celgene, Alexion, Agios, Jazz, and Novartis.

© 2020 by The American Society of Hematology.

Figures

Figure 1.

RFS following HCT in patients with FLT3+AML randomized to receive sorafenib or placebo.

Figure 2.

RFS following HCT in patients with MDS or AML randomized to receive maintenance azacitidine vs supportive care.